XML 61 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Schedule of Contractual Clinical Trials (Details)
 9 Months Ended
Sep. 30, 2023
Integer
Phase 1b [Member]  
Other Commitments [Line Items]  
Description of Clinical Trial LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer
Estimated Start Date March 2021
Estimated End Date March 2026
Phase 1b [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 14
Phase 1b [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 36
Phase 1b Two [Member]  
Other Commitments [Line Items]  
Description of Clinical Trial LB-100 combined with doxorubicin in sarcoma
Estimated Start Date June 2023
Estimated End Date June 2024
Phase 1b Two [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 9
Phase 1b Two [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 18
Randomized Phase 2 [Member]  
Other Commitments [Line Items]  
Description of Clinical Trial Doxorubicin with or without LB-100 in sarcoma
Estimated Start Date July 2024
Estimated End Date June 2026
Number of Patients in Trial 150
Clinical Trial Phase 1b 2 [Member]  
Other Commitments [Line Items]  
Description of Clinical Trial LB-100 combined with dostarlimab in ovarian clear cell carcinoma
Estimated Start Date March 2024
Estimated End Date December 2025
Number of Patients in Trial 21